[go: up one dir, main page]

WO2013073968A3 - Agents for modulation of cell signalling - Google Patents

Agents for modulation of cell signalling Download PDF

Info

Publication number
WO2013073968A3
WO2013073968A3 PCT/NZ2012/000164 NZ2012000164W WO2013073968A3 WO 2013073968 A3 WO2013073968 A3 WO 2013073968A3 NZ 2012000164 W NZ2012000164 W NZ 2012000164W WO 2013073968 A3 WO2013073968 A3 WO 2013073968A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
agents
cells
cell signalling
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NZ2012/000164
Other languages
French (fr)
Other versions
WO2013073968A2 (en
Inventor
Keryn Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meat and Livestock Autralia Ltd
Australian Meat and Live Stock Research and Development Corp
Callaghan Innovation Research Ltd
Original Assignee
Meat and Livestock Autralia Ltd
Australian Meat and Live Stock Research and Development Corp
Industrial Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903730A external-priority patent/AU2011903730A0/en
Application filed by Meat and Livestock Autralia Ltd, Australian Meat and Live Stock Research and Development Corp, Industrial Research Ltd filed Critical Meat and Livestock Autralia Ltd
Publication of WO2013073968A2 publication Critical patent/WO2013073968A2/en
Publication of WO2013073968A3 publication Critical patent/WO2013073968A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to methods and peptides for the modulation of gap junction communication between cells. In particular the present invention relates to methods for modulating gap junction communication in mammalian cells, comprising treating the cells with an effective amount of a peptide having the amino acid sequence FHPSS (SEQ ID NO: 3), or a variant form thereof having at least 60% sequence identity with the amino acid sequence and being at least 4 amino acids in length.
PCT/NZ2012/000164 2011-09-12 2012-09-12 Agents for modulation of cell signalling Ceased WO2013073968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011903730A AU2011903730A0 (en) 2011-09-12 Agents for modulation of cell signalling
AU2011903730 2011-09-12

Publications (2)

Publication Number Publication Date
WO2013073968A2 WO2013073968A2 (en) 2013-05-23
WO2013073968A3 true WO2013073968A3 (en) 2013-06-20

Family

ID=48430320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2012/000164 Ceased WO2013073968A2 (en) 2011-09-12 2012-09-12 Agents for modulation of cell signalling

Country Status (1)

Country Link
WO (1) WO2013073968A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512139D0 (en) * 2015-07-10 2015-08-19 Zealand Pharma As Methods of treatment
IL281377B2 (en) * 2018-09-12 2025-01-01 Firststring Res Inc Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034629A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 21 human secreted proteins
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators
WO2009029991A1 (en) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
WO2012175741A2 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2013003647A2 (en) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034629A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 21 human secreted proteins
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
WO2009010733A2 (en) * 2007-07-15 2009-01-22 Zealand Pharma A/S Peptide gap junction modulators
WO2009029991A1 (en) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
WO2012175741A2 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2013003647A2 (en) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI Y-W. ET AL.: "Structure-activity relationship study of antioxidant peptides by QSAR modeling: the amino acid next to C-terminus affects the activity", JOURNAL OF PEPTIDE SCIENCE, vol. 17, no. 6, June 2011 (2011-06-01), pages 454 - 462 *
POOJARY B. ET AL.: "Synthetic studies on cyclic octapeptides: Yunnanin F and Hymenistatin", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 2005, pages 407 - 412 *

Also Published As

Publication number Publication date
WO2013073968A2 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
AR092712A1 (en) A PROTEIN WITH CETOSE ACTIVITY 3-EPIMERASE
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2014011459A (en) Charged nutritive proteins and methods.
CO6491059A2 (en) DIFFERENTIATION OF MESENQUIMAL MOTHER CELLS
HK1214739A1 (en) Engineered secreted proteins and methods
IN2014KN01713A (en)
NZ701125A (en) Improved chymosine enzyme variants
UA103216C2 (en) Polypeptide with xylanase activity
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
EA201000327A1 (en) PROTEIN
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
PH12012502520A1 (en) Plants having enhanced yield-related traits and method for making the same
MX2014011614A (en) Nutritive fragments and proteins with low or no phenylalanine and methods.
MX2015007421A (en) Modified coiled coil type proteins having improved properties.
IN2014DN09963A (en)
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
MX2015001542A (en) Method.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
AR132574A2 (en) A FUSION PEPTIDE COMPRISING AN ISOFORM OF THE TGF-β RECEPTOR II FUSED TO A LIGAND, A POLYNUCLEOTIDE EXPRESSING IT, A VECTOR, AND A CELL
WO2013073968A3 (en) Agents for modulation of cell signalling
MY187334A (en) Xylanase
NZ600818A (en) Cyclic peptides for the regulation of vectorial ion channels
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
WO2012031103A3 (en) Inhibitors of bcl-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12850121

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12850121

Country of ref document: EP

Kind code of ref document: A2